SEATTLE — In the phase 2 ENVISION trial, UBX1325 failed to meet the primary endpoint of noninferiority to aflibercept in wet age-related macular degeneration but showed comparable outcomes in a subgroup of advanced cases.
The results of part A of this proof-of-concept study were presented at the American Society of Retina Specialists annual meeting by Raj Maturi, MD, who explained that UBX1325 (foselutoclax, Unity Biotechnology) inhibits the function of specific profibrotic, proinflammatory factors in senescent cells.
“Senescent cells are no longer dividing, stressed, but